RENOVUE-65
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 58m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENOVUE-65 is an injectable pharmaceutical product approved by Bracco in 1978 with an unknown mechanism of action and indication profile. The specific therapeutic area and patient population cannot be determined from available data.
LOE Approaching
With LOE approaching and zero linked job postings, the product faces significant commercial wind-down; career opportunities are likely limited to legacy support roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RENOVUE-65 presents minimal career opportunity for pharma professionals; zero linked job postings reflect the product's terminal lifecycle stage. Career growth is unlikely given the absence of clinical development, limited commercial momentum, and impending exclusivity loss.
Company
Worked on RENOVUE-65 at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.